**To the Editor:** Despite improved public health, serious infections with nontyphoidal *Salmonella enterica* remain a major clinical and public health concern in Thailand and worldwide ([@R1],[@R2]). Life-threatening *Salmonella* infections resistant to fluoroquinolones, extended-spectrum cephalosporins, or both, have been increasingly reported ([@R3]). Use of antimicrobial drugs for disease prevention and growth promotion in food animals has been implicated in this increase in drug resistance ([@R4]). Because of extensive global travel, such increases affect the medical community domestically and internationally ([@R5]). We report a pilot survey of drug resistance in *Salmonella* spp. in Thailand.

We studied archival nontyphoidal *Salmonella* isolates from bacteremic patients at King Chulalongkorn Memorial Hospital from January 2003 to October 2005 and from bacteremic patients in Thailand sent to the World Health Organization National *Salmonella* and *Shigella* Center in Bangkok during the first half of 2005. The isolates from these archives were nonoverlapping and were kept frozen at −80°C. Isolates were divided into *Salmonella* serovar Choleraesuis and other nontyphoidal *Salmonella* (non-Choleraesuis) because we observed that Choleraesuis isolates show a higher frequency of resistance to fluoroquinolones and extended-spectrum cephalosporins than non-Choleraesuis isolates. A standard Etest method (AB Biodisk, Solna, Sweden) was used to evaluate MICs for nalidixic acid, ciprofloxacin, and ceftriaxone. Susceptibility was defined according to the 2005 criteria for *Salmonella* of the Clinical Laboratory Standards Institute (CLSI, formerly NCCLS) ([@R6]).

Isolates showed high frequencies of antimicrobial drug resistance ([Figure](#F1){ref-type="fig"}). All *S*. Choleraesuis isolates with ceftriaxone resistance also showed high levels of resistance to nalidixic acid (MIC ≥256 µg/mL); most of these also had reduced susceptibility to ciprofloxacin (MIC ≥0.125 µg/mL). Of 73 nalidixic acid--resistant *Salmonella* isolates, 55 (75%) required a ciprofloxacin MIC ≥0.125 µg/mL, 14 (19%) required an MIC of 0.094 µg/mL, and 4 (6%) required an MIC of 0.064 µg/mL. One patient with aortitis caused by ceftriaxone-resistant *S.* Choleraesuis died of a ruptured mycotic aneurysm.
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In the food animal industry, the effect of using antimicrobial drugs has long been a subject of concern ([@R7]--[@R9]). Evidence from molecular epidemiologic studies ([@R9]) suggests that these concerns are genuine and that serious problems must be addressed. This concern is also supported by reports of fatal, invasive, nontyphoidal *Salmonella* infections resistant to quinolones or extended-spectrum cephalosporins ([@R7]*,*[@R10]). In Thailand, enrofloxacin, a veterinary fluoroquinolone, is used in animals in the poultry, swine, and seafood industries. Ceftiofur, a third-generation cephalosporin, is used extensively in swine for treatment and prevention of disease and for growth promotion. When compared with previous susceptibility patterns ([@R5]), current nontyphoidal *Salmonella* infections in humans in Thailand are more resistant to quinolones and cephalosporins. Susceptibility to nalidixic acid correlates well with reduced susceptibility to ciprofloxacin. An alarming increase in ceftriaxone resistance in *S*. Choleraesuis may be associated with inappropriate cephalosporin use in swine farming. Major revisions in current policies for use of antimicrobial drugs in food animals in Thailand are warranted.
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